NanoViricides, Inc. (NNVC)
NNVC moved a median of +0.01% 30 minutes after news, and 0.00% by the close. How NNVC actually reacts to news — the realized, point-in-time move the market made, measured across 164 labeled events over the last three years with zero look-ahead.
NNVC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 161 |
| 30-min | +0.01% | 52% | 164 |
| 60-min | 0.00% | 49% | 164 |
| to close | 0.00% | 46% | 162 |
| Middle 50% of NNVC reactions | -1.33% to +1.81% |
|---|---|
| Median reaction (30-min) | +0.01% |
| Measured reactions | 164 |
Half of all NanoViricides, Inc. news events land between -1.33% and +1.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NNVC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NNVC's baseline. Nothing else.
Recent NNVC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides | Press release | ACCESS Newswire | +1.61% | +6.45% | |
| Form DEF 14A NANOVIRICIDES, INC. For: Nov 21 | SEC filing · Form DEF | SEC EDGAR | -1.12% | -1.87% | |
| NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 | Press release | ACCESS Newswire | +0.57% | -3.45% | |
| NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives | Press release | ACCESS Newswire | +1.55% | +12.40% | |
| Form 8-K NANOVIRICIDES, INC. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -4.41% | -4.41% | |
| NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials | Press release | ACCESS Newswire | -0.99% | -14.47% | |
| Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides | Press release | ACCESS Newswire | -0.14% | +4.17% | |
| Form 10-K NANOVIRICIDES, INC. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -0.99% | -14.47% | |
| Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides | Press release | ACCESS Newswire | +0.31% | -6.79% | |
| A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat | Press release | GlobeNewswire | +0.94% | -1.87% | |
| Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in ?DR Congo with 48% Crude Fatality Rate, Says NanoViricides | Press release | ACCESS Newswire | +0.94% | -1.87% | |
| Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo | Press release | ACCESS Newswire | +0.00% | -2.70% | |
| Form EFFECT NANOVIRICIDES, INC. | SEC filing · Form EFFECT | SEC EDGAR | +0.81% | -2.42% | |
| While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles | Press release | ACCESS Newswire | +1.55% | -3.10% | |
| Form S-3 NANOVIRICIDES, INC. | SEC filing · Form S-3 | SEC EDGAR | -0.76% | -3.05% | |
| The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak | Press release | ACCESS Newswire | +11.30% | — | |
| Form 8-K NANOVIRICIDES, INC. For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.31% | |
| NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial | Press release | ACCESS Newswire | +3.81% | +11.03% | |
| NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering | Press release | ACCESS Newswire | +2.67% | -1.33% | |
| As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola | Press release | ACCESS Newswire | +1.30% | -1.30% | |
| Form 8-K NANOVIRICIDES, INC. For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | -2.23% | |
| As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo | Press release | ACCESS Newswire | +7.89% | +8.55% | |
| Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | Press release | ACCESS Newswire | +2.76% | +6.90% | |
| As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo | Press release | ACCESS Newswire | +1.89% | +13.64% | |
| Form EFFECT NANOVIRICIDES, INC. | SEC filing · Form EFFECT | SEC EDGAR | +2.18% | +0.00% | |
| US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher | Press release | ACCESS Newswire | +2.18% | +0.00% | |
| Form DEL AM NANOVIRICIDES, INC. | SEC filing · Form DEL | SEC EDGAR | +1.09% | -1.17% | |
| NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo | Press release | ACCESS Newswire | -3.16% | -6.05% | |
| Form DEL AM NANOVIRICIDES, INC. | SEC filing · Form DEL | SEC EDGAR | +0.00% | -0.74% | |
| Form EFFECT NANOVIRICIDES, INC. | SEC filing · Form EFFECT | SEC EDGAR | -6.99% | -4.89% | |
| As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo | Press release | ACCESS Newswire | +7.80% | +10.16% | |
| Form S-3 NANOVIRICIDES, INC. | SEC filing · Form S-3 | SEC EDGAR | -6.99% | -4.89% | |
| As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies | Press release | ACCESS Newswire | +0.00% | +1.42% | |
| Form S-3 NANOVIRICIDES, INC. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +1.42% | |
| In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides | Press release | ACCESS Newswire | +0.63% | -5.03% | |
| Form 8-K NANOVIRICIDES, INC. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -1.27% | |
| Form 8-K NANOVIRICIDES, INC. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -1.27% | |
| Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides | Press release | ACCESS Newswire | -1.01% | +2.03% | |
| NanoViricides Announces Closing of ~$2 Million Registered Direct Offering | Press release | ACCESS Newswire | -4.52% | +2.58% | |
| Form 10-Q NANOVIRICIDES, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.59% | -5.73% | |
| NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering | Press release | ACCESS Newswire | -1.59% | -5.73% | |
| NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II | Press release | ACCESS Newswire | -1.59% | -5.73% | |
| Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides | Press release | ACCESS Newswire | -4.04% | -7.45% | |
| NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA | Press release | ACCESS Newswire | +0.00% | +12.78% | |
| Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides | Press release | ACCESS Newswire | +0.78% | -1.56% | |
| Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides | Press release | ACCESS Newswire | -1.10% | -0.92% | |
| Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides | Press release | ACCESS Newswire | -1.05% | +0.48% | |
| NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete | Press release | ACCESS Newswire | -0.01% | +16.16% | |
| Form D NANOVIRICIDES, INC. | SEC filing · Form D | SEC EDGAR | +0.13% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NNVC section they belong to.
Where else NNVC is measured.
NNVC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Minerva Neurosciences, Inc (NERV) | 164 | 0.00% | 48% |
| NIGHTSTAR THERAPEUTICS PLC AMERICAN DEPOSITARY SHA (NITE) | 164 | -0.04% | 28% |
| Matinas Biopharma Holdings, Inc. (MTNB) | 161 | -0.53% | 39% |
| NanoVibronix, Inc. (NAOV) | 161 | -0.40% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NanoViricides, Inc.'s median reaction calculated?
Every labeled NNVC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 164 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of NNVC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NNVC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.